Welcome to Merz Therapeutics North America

Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is a global healthcare leader dedicated to improving the lives of patients around the world. With our relentless research, development, and culture of innovation, we strive to serve unmet patient needs and realize better outcomes.

Our Merz Therapeutics North America business is comprised of affiliates in the U.S. and Canada and has regional headquarters in Raleigh, N.C.

News

MERZ THERAPEUTICS TO PRESENT KEY DATA ON XEOMIN® (incobotulinumtoxinA) AT TOXINS 2021 VIRTUAL CONFERENCE

Merz Therapeutics announced today the presentation of data from 18 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2021: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins, taking place virtually January 16 and 17.

Read More

INFOGRAPHIC: XEOMIN® (incobotulinumtoxinA) PEDIATRIC CHRONIC SIALORRHEA

XEOMIN® (incobotulinumtoxinA) is now approved by the FDA for the treatment of patients aged 2 years and older with chronic sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication. Download our infographic detailing our latest approval.

Read More

FDA APPROVES PEDIATRIC INDICATION FOR XEOMIN® (incobotulinumtoxinA) FOR THE TREATMENT OF CHRONIC SIALORRHEA

Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for XEOMIN® (incobotulinumtoxinA) for the treatment of patients aged 2 years and older with chronic sialorrhea, or drooling. XEOMIN is the first and only FDA-approved neuromodulator with this indication and was granted a priority review designation upon acceptance by the FDA.

Read More